SOURCE: CoActive health Communications

CoActive health Communications

March 21, 2011 08:30 ET

CoActive Health Communications Names Vice President to Lead and Grow United States Client Services

Amy Berry Brings 15 Years of Healthcare Experience in Pharmaceuticals, Biotech and Device/Diagnostics

SAN FRANCISCO, CA--(Marketwire - March 21, 2011) -   CoActive Health Communications, an award-winning full-service healthcare communications firm, today announced that Amy Berry, a communications professional with 15 years of experience in designing and executing strategic healthcare programs, was appointed as the agency's new Vice President based in the West Coast office. Berry will oversee existing client services while expanding the agency's United States communications franchise. She joins Carmen Caricchio, president and owner, as Caricchio focuses on increasing CoActive's presence in Australia and internationally.

"Bringing Amy on board was a strategic decision to diversify and build CoActive's presence among life sciences/biotech, healthcare and medical technology companies," said Caricchio. "With her rich experience in multiple disease areas covering pharmacologics, biologics and medical devices, I'm confident that Amy will provide our clients with expert counsel while we extend our reach to companies overseas that look to increase their position in the U.S. healthcare market."

Most recently, Berry managed product communications for the BioOncology franchise of Genentech, a member of the Roche Group. There, she managed three FDA approvals and subsequent launches for biologic cancer drugs Avastin and Rituxan. She also oversaw the communications programs for numerous clinical data and commercial milestones for many other medicines or investigational medicines including RG7204, a BRAF-inhibitor in clinical trials for advanced melanoma, one of the most deadly and difficult-to-treat cancers. For each product, she was deeply involved in all forms of media communications on behalf of Genentech and its product development partners.

Prior to Genentech, Berry managed strategic communications for a number of clients including Carl Zeiss Meditec, StemLifeLine and the University of California San Francisco's Orthopaedic Trauma Institute through her previous partnership with CoActive Health Communications. In addition, she provided consulting support to Roche Molecular Diagnostics and HUYA Biosciences.

Berry has also worked for international communications agencies Dorland Global Healthcare Communications, GCI Group (Grey Global) and Kane & Finkel. In each of these positions, she supported a broad range of clients in different therapeutic areas such as ophthalmology, oncology, neurology, HIV, osteoporosis and others.

About CoActive Health Communications
CoActive Health Communications is an award-winning full-service communications firm dedicated exclusively to the healthcare, life sciences and medical technology industries. We specialize in creating an identity for our clients, introducing new therapeutics and medical devices to the marketplace and publicizing the ways in which patients are benefiting from new breakthroughs in treatment.

Contact Information